EGFR and head and neck squamous cell carcinoma: However, constitutively active EGFR variant (EGFRvIII) promotes resistance against cetuximab in HNSCC.233 While the therapeutic efficacy of EGFR inhibition remains unclear and controversial in HPV+ve HNSCC,234 many other EGFR inhibitors including mabs (panitumumab or nimotuzumab) and small-molecule inhibitors (lapatinib, erlotinib, gefitinib, and afatinib), either alone or along with CRT are currently being investigated in many clinical trials (reviewed in ref. 235).